Allogeneic hematopoietic cell transplant (HCT) recipients are at risk for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Routine prophylaxis with acyclovir is recommended during periods of immunosuppression. Brincidofovir (BCV, CMX001), a lipid conjugate of cidofovir, has shown in vitro activity against HSV/VZV, but has not been formally studied for HSV/VZV prophylaxis. We report 
patients were adults and 22 (73%) patients received T-cell depleted HCT. The most common indications for BCV were cytomegalovirus in 12 patients (40%) and adenovirus in 11 patients (37%). One patient was treated for acyclovir-resistant HSV and one for disseminated VZV. There were two breakthrough cases of HSV infection during 2170 patient-days. There were no cases of breakthrough VZV infection.
The overall rate of breakthrough HSV infection was 1.0 per 1000 patient-days, without any breakthrough VZV infections. Our study provides the only availablealbeit limited-evidence on the potential efficacy of BCV for HSV/VZV prophylaxis in HCT patients. Additional studies are needed to further assess the efficacy and safety of BCV in the setting.
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| INTRODUC TI ON

| ME THODS
| Study design
This is a single-center 5-year retrospective observational study of 
| Data collection and definitions
Data were extracted from medical, pharmacy, and microbiology re- Steroid doses were calculated during the duration of BCV treatment.
Steroid doses were multiplied by their approximate equivalent dose using prednisone dose as a base. 
| RE SULTS
| Baseline patient characteristics
| Brincidofovir administration data
The 
| Breakthrough infections
Two (6.7%) patients (#12 and #28) developed breakthrough HSV infections, for an overall rate of 1.0 HSV infection per 1000 patient-days. There were no VZV infections observed during the study period.
| Patient #12
A 58-year-old male with acute lymphoblastic leukemia (ALL) who re- The recurrence was treated successfully with an additional dose of BCV 100 mg.
| Patient #28
A 57-year-old female with ALL received double umbilical cord blood 
| D ISCUSS I ON
Clinical data on the efficacy of BCV in HSV/VZV prophylaxis are In conclusion, in a highly immunocompromised cohort of HCT recipients, the overall rate of breakthrough HSV infection was 1.0 per 1000 patient-days, without any breakthrough VZV infections.
Despite its significant limitations, including its retrospective approach and limited numbers of patients included, our study provides the only available-albeit limited-evidence on the potential efficacy of BCV for HSV/VZV prophylaxis in HCT patients. Additional studies are needed to further assess the efficacy and safety of BCV as potential single-agent prophylaxis against multiple dsDNA viruses in high-risk patients.
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